These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7609359)

  • 1. [Combined immunotherapy using interferon-alpha, interleukin-2 and lymphokine-activated killer cells--improvement of quality of life in patients with advanced renal cell carcinoma].
    Watanabe J; Hattori T; Satoh M; Akimoto M
    Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1156-63. PubMed ID: 7609359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
    Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
    Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2.
    Hayakawa M; Hatano T; Ogawa Y; Gakiya M; Ogura H; Osawa A
    Urol Int; 1994; 53(3):117-24. PubMed ID: 7645136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
    Yeung AW; Pang YK; Tsang YC; Wong SW; Leung JS
    Cancer; 1993 Jun; 71(11):3633-9. PubMed ID: 8387882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells.
    Kruit WH; Schmitz PI; Stoter G
    Cancer Immunol Immunother; 1999 Sep; 48(6):331-5. PubMed ID: 10473808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
    Bukowski RM
    Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
    Gambacorti-Passerini C; Hank JA; Albertini MR; Borchert AA; Moore KH; Schiller JH; Bechhofer R; Borden EC; Storer B; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):43-8. PubMed ID: 8435431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
    Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.